Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MSORK
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CN106459055B ADC-7
|
|||||
| Synonyms |
CN106459055B_ADC-7
Click to Show/Hide
|
|||||
| Organization |
Pfizer Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.9
|
|||||
| Antibody Name |
IL13Ralpha2-AB08-v1.0/1.0
|
Antibody Info | ||||
| Antigen Name |
Interleukin-13 (IL13)
|
Antigen Info | ||||
| Payload Name |
CN106459055B ADC-7 payload
|
Payload Info | ||||
| Linker Name |
CN106459055B ADC-7 linker
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 2 ng/mL | Positive IL13 expression (IL13+++/++) | ||
| Method Description |
Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.
Click to Show/Hide
|
||||
| In Vitro Model | Amelanotic melanoma | A-375 cells | CVCL_0132 | ||